「小普日?qǐng)?bào)」2023年9月22日熱點(diǎn)速遞

關(guān)鍵詞
索拉奈珠單抗?曲美替尼 司美格魯肽 納武利尤單抗 冷球蛋白血癥?奧馬珠單抗 依瑞奈尤單抗
?
#今日行業(yè)熱點(diǎn)#
①The New England Journal of Medicine:Trial of Solanezumab in Preclinical Alzheimer’s Disease
臨床試驗(yàn):靶向aβ中間結(jié)構(gòu)域的單克隆抗體索拉奈珠單抗(solanezumab)用于臨床前阿爾茨海默病的Ⅲ期試驗(yàn)
DOI: 10.1056/NEJMoa2305032
②The New England Journal of Medicine:Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations
臨床試驗(yàn):達(dá)非尼聯(lián)合曲美替尼用于BRAF V600突變的小兒膠質(zhì)瘤的Ⅱ期試驗(yàn)
DOI: 10.1056/NEJMoa2303815
③The New England Journal of Medicine:Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
臨床試驗(yàn):司美格魯肽在射血分?jǐn)?shù)保留的心力衰竭合并肥胖患者中的隨機(jī)、對(duì)照試驗(yàn)
DOI: 10.1056/NEJMoa2306963
④Genome Medicine:Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence
晚期肝細(xì)胞癌(HCC)的新輔助藥物卡博替尼 (Cabozantinib)和納武利尤單抗的空間轉(zhuǎn)錄組學(xué)分析確定了耐藥和復(fù)發(fā)的獨(dú)立機(jī)制
DOI: 10.1186/s13073-023-01218-y
⑤British Journal Of Haematology:Clinical and clonal characteristics of monoclonal immunoglobulin M-associated type I cryoglobulinaemia
單克隆免疫球蛋白M(IgM)相關(guān)I型冷球蛋白血癥的臨床和克隆特征
DOI: 10.1111/bjh.19112
⑥International Forum of Allergy & Rhinology:Combination of omalizumab with allergen immunotherapy versus immunotherapy alone for allergic diseases: A meta-analysis of randomized controlled trials
奧馬珠單抗聯(lián)合過(guò)敏原免疫療法與單獨(dú)免疫療法用于過(guò)敏性疾病:一項(xiàng)隨機(jī)對(duì)照試驗(yàn)的薈萃分析
DOI: 10.1002/alr.23268
⑦抗TMPRSS6單克隆抗體9MW3011獲得美國(guó)FDA快速通道認(rèn)定(FTD),用于真性紅細(xì)胞增多癥(PV)
⑧第三代表皮生長(zhǎng)因子受體酪氨酸激酶抑制劑(EGFR-TKI)奧希替尼新適應(yīng)癥上市申請(qǐng)獲受理
⑨全人源單克隆抗體依瑞奈尤單抗(Erenumab)在華獲批上市,用于預(yù)防成人偏頭痛
⑩新型NMDA受體通道阻斷劑REL-1017(右美沙酮)用于重度抑郁癥(MDD)的Ⅲ期擴(kuò)展REL-1017-310研究結(jié)果積極
科學(xué)探索的世界充滿挑戰(zhàn),AtaGenix致敬每一位拓荒者,更致力于成為您信賴的合作伙伴!